Signadori Bio Raises €11.1M for Solid Tumor Immunotherapy

Paris-based Signadori Bio has successfully closed a seed funding round, amassing €11.1 million to propel its innovative in vivo monocyte engineering platform for solid tumors. The substantial capital infusion was bolstered by new investment from Taiho Ventures, alongside continued support from existing backers Sofinnova Partners and Invivo Partners. This financing marks a significant step for the preclinical biopharmaceutical firm as it aims to revolutionize solid tumor treatment.

The newly acquired funds will be strategically deployed to advance Signadori Bio's lead program, SiB-2101, towards candidate nomination. Furthermore, the investment will fuel the ongoing development of the company's proprietary platform, which focuses on engineering monocytes directly within the patient to enhance anti-tumor immune responses. Expansion of both the scientific and operational teams is also a key priority, ensuring the company is well-equipped for its next phase of growth.

Signadori Bio's unique approach centers on harnessing the innate immune system by reprogramming monocytes to combat the immunosuppressive tumor microenvironment. This strategy seeks to overcome critical limitations inherent in current immunotherapies and autologous cell therapies, particularly for the challenging landscape of solid tumors. The company's technology, originating from research at Gustave Roussy, aims to create an off-the-shelf solution that is both scalable and broadly applicable.

“This funding represents a pivotal moment for Signadori Bio,” stated Dr. Selwyn Ho, CEO of Signadori Bio. “We are building on promising preclinical data and are eager to move our platform into clinical development. Our in vivo monocyte engineering offers the potential for a new generation of immunotherapies that are more accessible and effective for patients battling solid tumors. We are thrilled to welcome Taiho Ventures to our investor base, joining our committed partners Sofinnova Partners and Invivo Partners.”

Seiji Miyahara, Partner & Senior Investment Director at Taiho Ventures, highlighted the company's differentiated strategy. “Signadori Bio is pursuing a highly distinct path in immuno-oncology by targeting monocytes and utilizing in vivo engineering. The compelling preclinical results and robust scientific foundation position them to address significant unmet needs in solid tumor treatment. We are enthusiastic about supporting the team’s progress.”

The immuno-oncology sector continues to attract significant investment, with a growing focus on novel mechanisms of action beyond traditional checkpoint inhibitors. Companies developing cell therapies and innate immune cell modulators are seeing increased interest, driven by the potential to treat a wider patient population and overcome resistance mechanisms. The market for solid tumor treatments alone is projected to reach hundreds of billions of dollars globally in the coming years, underscoring the immense therapeutic and commercial opportunity.

Matthieu Coutet, Chair of the Board at Signadori Bio and Partner at Sofinnova Partners, added, “Since its inception, Signadori Bio has demonstrated substantial progress in validating its platform and showcasing the therapeutic promise of p21-driven monocyte reprogramming. This financing will empower the company to accelerate its development trajectory and bring its innovative therapies closer to clinical reality.”